No Cover Image

Journal article 474 views 67 downloads

Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide

Paula Row, Riaz Jannoo, Zhidao Xia, Paula E. Row, Venkat Kanamarlapudi Orcid Logo

Biomolecules, Volume: 13, Issue: 2, Start page: 356

Swansea University Authors: Paula Row, Venkat Kanamarlapudi Orcid Logo

  • 63097.pdf

    PDF | Version of Record

    © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

    Download (2.24MB)

Check full text

DOI (Published version): 10.3390/biom13020356

Abstract

The IL-13Rα2 cell surface receptor is highly expressed in tumours such as prostate cancer. In this report, we evaluated the hypothesis that prostate cancer cells with enhanced IL-13Rα2 expression are a suitable target for the hybrid lytic peptide (Pep-1-Phor21) peptide, which is generated by fusing...

Full description

Published in: Biomolecules
ISSN: 2218-273X
Published: MDPI AG 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63097
first_indexed 2023-05-10T14:16:59Z
last_indexed 2024-11-15T18:00:54Z
id cronfa63097
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2024-02-02T08:35:50.7234005</datestamp><bib-version>v2</bib-version><id>63097</id><entry>2023-04-06</entry><title>Targeting of the Interleukin-13 Receptor (IL-13R)&#x3B1;2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide</title><swanseaauthors><author><sid>99bb528b2f8fb62aabbdad101d53ba96</sid><firstname>Paula</firstname><surname>Row</surname><name>Paula Row</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>63741801137148abfa4c00cd547dcdfa</sid><ORCID>0000-0002-8739-1483</ORCID><firstname>Venkat</firstname><surname>Kanamarlapudi</surname><name>Venkat Kanamarlapudi</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-04-06</date><deptcode>MEDS</deptcode><abstract>The IL-13R&#x3B1;2 cell surface receptor is highly expressed in tumours such as prostate cancer. In this report, we evaluated the hypothesis that prostate cancer cells with enhanced IL-13R&#x3B1;2 expression are a suitable target for the hybrid lytic peptide (Pep-1-Phor21) peptide, which is generated by fusing the IL-13R&#x3B1;2 specific ligand (Pep-1) and a cell membrane disrupting lytic peptide (Phor21). The expression of IL-13R&#x3B1;2 mRNA and protein in prostate cancer tissues and cell lines was assessed via real-time PCR (RT-PCR) and immunoblotting. The effect of Pep-1-Phor21 on the viability of prostate cancer cells grown in monolayers (2D) and microtissue spheroids (3D) was assessed via CellTox green cytotoxic assay. IL-13R&#x3B1;2 expression and Pep-1-Phor21-mediated killing were also determined in the cells treated with epigenetic regulators (Trichostatin A (TSA) and 5-aza-2 deoxycytidine (5-Aza-dC)). The hybrid lytic peptide cytotoxic activity correlated with the expression of IL-13R&#x3B1;2 in prostate cancer cell lines cultured as monolayers (2D) or 3D spheroids. In addition, TSA or 5-Aza-dC treatment of prostate cancer cells, particularly those with low expression of IL-13R&#x3B1;2, enhanced the cells' sensitivity to the lytic peptide by increasing IL-13R&#x3B1;2 expression. These results demonstrate that the Pep-1-Phor21 hybrid lytic peptide has potent and selective anticancer properties against IL-13R&#x3B1;2-expressing prostate cancer cells.</abstract><type>Journal Article</type><journal>Biomolecules</journal><volume>13</volume><journalNumber>2</journalNumber><paginationStart>356</paginationStart><paginationEnd/><publisher>MDPI AG</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2218-273X</issnElectronic><keywords>3D spheroids; IL-13R&#x3B1;2; Pep-1; Phor21; epigenetics; hybrid lytic peptide; prostate cancer; therapeutic peptide</keywords><publishedDay>12</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-02-12</publishedDate><doi>10.3390/biom13020356</doi><url>http://dx.doi.org/10.3390/biom13020356</url><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Other</apcterm><funders/><projectreference/><lastEdited>2024-02-02T08:35:50.7234005</lastEdited><Created>2023-04-06T17:37:22.5511457</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Paula</firstname><surname>Row</surname><order>1</order></author><author><firstname>Riaz</firstname><surname>Jannoo</surname><order>2</order></author><author><firstname>Zhidao</firstname><surname>Xia</surname><order>3</order></author><author><firstname>Paula E.</firstname><surname>Row</surname><order>4</order></author><author><firstname>Venkat</firstname><surname>Kanamarlapudi</surname><orcid>0000-0002-8739-1483</orcid><order>5</order></author></authors><documents><document><filename>63097__27413__33b5212dae684d64a3b9c3ce898705e7.pdf</filename><originalFilename>63097.pdf</originalFilename><uploaded>2023-05-10T15:16:04.4957891</uploaded><type>Output</type><contentLength>2351615</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2024-02-02T08:35:50.7234005 v2 63097 2023-04-06 Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide 99bb528b2f8fb62aabbdad101d53ba96 Paula Row Paula Row true false 63741801137148abfa4c00cd547dcdfa 0000-0002-8739-1483 Venkat Kanamarlapudi Venkat Kanamarlapudi true false 2023-04-06 MEDS The IL-13Rα2 cell surface receptor is highly expressed in tumours such as prostate cancer. In this report, we evaluated the hypothesis that prostate cancer cells with enhanced IL-13Rα2 expression are a suitable target for the hybrid lytic peptide (Pep-1-Phor21) peptide, which is generated by fusing the IL-13Rα2 specific ligand (Pep-1) and a cell membrane disrupting lytic peptide (Phor21). The expression of IL-13Rα2 mRNA and protein in prostate cancer tissues and cell lines was assessed via real-time PCR (RT-PCR) and immunoblotting. The effect of Pep-1-Phor21 on the viability of prostate cancer cells grown in monolayers (2D) and microtissue spheroids (3D) was assessed via CellTox green cytotoxic assay. IL-13Rα2 expression and Pep-1-Phor21-mediated killing were also determined in the cells treated with epigenetic regulators (Trichostatin A (TSA) and 5-aza-2 deoxycytidine (5-Aza-dC)). The hybrid lytic peptide cytotoxic activity correlated with the expression of IL-13Rα2 in prostate cancer cell lines cultured as monolayers (2D) or 3D spheroids. In addition, TSA or 5-Aza-dC treatment of prostate cancer cells, particularly those with low expression of IL-13Rα2, enhanced the cells' sensitivity to the lytic peptide by increasing IL-13Rα2 expression. These results demonstrate that the Pep-1-Phor21 hybrid lytic peptide has potent and selective anticancer properties against IL-13Rα2-expressing prostate cancer cells. Journal Article Biomolecules 13 2 356 MDPI AG 2218-273X 3D spheroids; IL-13Rα2; Pep-1; Phor21; epigenetics; hybrid lytic peptide; prostate cancer; therapeutic peptide 12 2 2023 2023-02-12 10.3390/biom13020356 http://dx.doi.org/10.3390/biom13020356 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Other 2024-02-02T08:35:50.7234005 2023-04-06T17:37:22.5511457 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Paula Row 1 Riaz Jannoo 2 Zhidao Xia 3 Paula E. Row 4 Venkat Kanamarlapudi 0000-0002-8739-1483 5 63097__27413__33b5212dae684d64a3b9c3ce898705e7.pdf 63097.pdf 2023-05-10T15:16:04.4957891 Output 2351615 application/pdf Version of Record true © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license true eng https://creativecommons.org/licenses/by/4.0/
title Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
spellingShingle Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
Paula Row
Venkat Kanamarlapudi
title_short Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
title_full Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
title_fullStr Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
title_full_unstemmed Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
title_sort Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide
author_id_str_mv 99bb528b2f8fb62aabbdad101d53ba96
63741801137148abfa4c00cd547dcdfa
author_id_fullname_str_mv 99bb528b2f8fb62aabbdad101d53ba96_***_Paula Row
63741801137148abfa4c00cd547dcdfa_***_Venkat Kanamarlapudi
author Paula Row
Venkat Kanamarlapudi
author2 Paula Row
Riaz Jannoo
Zhidao Xia
Paula E. Row
Venkat Kanamarlapudi
format Journal article
container_title Biomolecules
container_volume 13
container_issue 2
container_start_page 356
publishDate 2023
institution Swansea University
issn 2218-273X
doi_str_mv 10.3390/biom13020356
publisher MDPI AG
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
url http://dx.doi.org/10.3390/biom13020356
document_store_str 1
active_str 0
description The IL-13Rα2 cell surface receptor is highly expressed in tumours such as prostate cancer. In this report, we evaluated the hypothesis that prostate cancer cells with enhanced IL-13Rα2 expression are a suitable target for the hybrid lytic peptide (Pep-1-Phor21) peptide, which is generated by fusing the IL-13Rα2 specific ligand (Pep-1) and a cell membrane disrupting lytic peptide (Phor21). The expression of IL-13Rα2 mRNA and protein in prostate cancer tissues and cell lines was assessed via real-time PCR (RT-PCR) and immunoblotting. The effect of Pep-1-Phor21 on the viability of prostate cancer cells grown in monolayers (2D) and microtissue spheroids (3D) was assessed via CellTox green cytotoxic assay. IL-13Rα2 expression and Pep-1-Phor21-mediated killing were also determined in the cells treated with epigenetic regulators (Trichostatin A (TSA) and 5-aza-2 deoxycytidine (5-Aza-dC)). The hybrid lytic peptide cytotoxic activity correlated with the expression of IL-13Rα2 in prostate cancer cell lines cultured as monolayers (2D) or 3D spheroids. In addition, TSA or 5-Aza-dC treatment of prostate cancer cells, particularly those with low expression of IL-13Rα2, enhanced the cells' sensitivity to the lytic peptide by increasing IL-13Rα2 expression. These results demonstrate that the Pep-1-Phor21 hybrid lytic peptide has potent and selective anticancer properties against IL-13Rα2-expressing prostate cancer cells.
published_date 2023-02-12T08:20:36Z
_version_ 1821392907581521920
score 11.04748

Similar Items